AU775516B2 - Ocular growth and nicotinic antagonists - Google Patents

Ocular growth and nicotinic antagonists Download PDF

Info

Publication number
AU775516B2
AU775516B2 AU30969/01A AU3096901A AU775516B2 AU 775516 B2 AU775516 B2 AU 775516B2 AU 30969/01 A AU30969/01 A AU 30969/01A AU 3096901 A AU3096901 A AU 3096901A AU 775516 B2 AU775516 B2 AU 775516B2
Authority
AU
Australia
Prior art keywords
nicotinic
eye
nicotinic antagonist
antagonist
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30969/01A
Other languages
English (en)
Other versions
AU3096901A (en
Inventor
Jon M. Lindstrom
Richard A. Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU3096901A publication Critical patent/AU3096901A/en
Application granted granted Critical
Publication of AU775516B2 publication Critical patent/AU775516B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU30969/01A 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists Ceased AU775516B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17687500P 2000-01-18 2000-01-18
US60/176875 2000-01-18
PCT/US2001/001692 WO2001052832A1 (fr) 2000-01-18 2001-01-18 Croissance oculaire et antagonistes nicotiniques

Publications (2)

Publication Number Publication Date
AU3096901A AU3096901A (en) 2001-07-31
AU775516B2 true AU775516B2 (en) 2004-08-05

Family

ID=22646232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30969/01A Ceased AU775516B2 (en) 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists

Country Status (10)

Country Link
EP (1) EP1272170A1 (fr)
JP (1) JP2003520228A (fr)
KR (1) KR20020081260A (fr)
CN (1) CN1418095A (fr)
AU (1) AU775516B2 (fr)
CA (1) CA2400803A1 (fr)
HK (1) HK1052464A1 (fr)
MX (1) MXPA02007039A (fr)
RU (1) RU2002120485A (fr)
WO (1) WO2001052832A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075720A2 (fr) * 2005-12-19 2007-07-05 Comentis, Inc. Preparations de mecamylamine topique pour administration oculaire et utilisations de celles-ci
FI20075498A (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
EP3593817A4 (fr) 2017-03-06 2021-04-07 Tsubota Laboratory, Inc. Modèle murin d'induction de la myopie et inhibiteur de stress du réticulum endoplasmique pour prévenir ou supprimer la myopie
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138008A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Procedes pour traiter les troubles neurocognitifs, la douleur chronique, et pour reduire l'inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029734T2 (de) * 1989-06-21 1997-05-28 Univ Pennsylvania Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method

Also Published As

Publication number Publication date
KR20020081260A (ko) 2002-10-26
CA2400803A1 (fr) 2001-07-26
HK1052464A1 (zh) 2003-09-19
JP2003520228A (ja) 2003-07-02
MXPA02007039A (es) 2003-09-25
AU3096901A (en) 2001-07-31
EP1272170A1 (fr) 2003-01-08
WO2001052832A1 (fr) 2001-07-26
RU2002120485A (ru) 2004-04-10
CN1418095A (zh) 2003-05-14

Similar Documents

Publication Publication Date Title
Atkins et al. Region‐specific induction of ΔFosB by repeated administration of typical versus atypical antipsychotic drugs
AU2023206175A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
US11690812B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
CN101415435A (zh) 用于治疗精神疾病和病症的支链淀粉和支链淀粉激动剂
Gustilo et al. Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons
PT2135603E (pt) Composições e métodos para aumentar a sensibilidade à insulina
WO2000024390A9 (fr) Procede et composition pour la modulation de l'amylose
US20060178307A1 (en) Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
US20030096831A1 (en) Ocular growth and nicotinic antagonists
Desager et al. Pharmacokinetic-pharmacodynamic relationships of H 1-antihistamines
AU775516B2 (en) Ocular growth and nicotinic antagonists
Nargeot et al. Molecular basis of the diversity of calcium channels in cardiovascular tissues
US20210330646A1 (en) Fascin binding compounds for spinogenesis
US8013118B2 (en) Lynx polypeptides
KR20230128037A (ko) Er형 미스센스 돌연변이를 갖는 환자에서, c형 니만픽병의 치료를 위한 아리모클로몰
KR102124845B1 (ko) 근력증진제로서 stim2 저해제의 용도
IL303969A (en) ugh
Kieselbach et al. Elevated levels of substance P in intraocular fluid in proliferative vitreoretinopathy
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
US20240050427A1 (en) Treatments for obsessive compulsive disorder
US20080226653A1 (en) Inhibition of Platelet Aggregation
US20090048146A1 (en) Use of agents that upregulate crystallin expression in the retina and optic nerve head
AU2020294309A1 (en) Use of arimoclomol in the treatment of niemann pick disease
Mulani Effect Of Topiramate On Body Weight, Systolic Blood Pressure And Spontaneous Motor Activity In Olanzapine Treated Rats
KR20220092026A (ko) 니만 픽병의 치료에서의 아리모클로몰의 용도

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT'S NAME TO READ: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA